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Opsoclonus myoclonus syndrome (OMS) is an extremely rare neurological syndrome typically affecting as few as 1 in 10,000,000
people annually. OMS is characterized by the presence of involuntary, saccadic eye movements, as well as ataxia, including gait
incoordination, rigidity, and tremor. The origin of OMS is unclear, but a significant percentage of OMS cases are indicative of an
underlying malignancy, most commonly neuroblastoma and small cell lung cancer. Here we describe an adult patient with OMS,
who was ultimately diagnosed with a small ductal adenocarcinoma of the pancreas. To our knowledge, this is the third published
report of an association between OMS and pancreatic malignancy, and the only case where the pancreatic malignancy was detected
prior to metastasis or autopsy at death. This case report highlights the importance of careful, aggressive malignancy screening with
OMS, as the pancreatic duct cut-off sign may be overlooked if pancreatic malignancy is not suspected.

1. Introduction
Opsoclonus myoclonus syndrome (OMS) is an extremely
rare autoimmune neurological syndrome typically affecting
as few as 1 in 10,000,000 people annually. The etiology of
OMS is thought to be paraneoplastic (e.g., malignancies) or
nonparaneoplastic (e.g., idiopathic, parainfectious) in origin
[1–3]. The clinical presentation of OMS is characterized by
the presence of involuntary and saccadic eye movements,
as well as ataxia, including gait incoordination, rigidity,
and tremor. The pathogenesis of OMS remains unclear;
however, it has been proposed that it could be the result of
dysfunctional motor neurons, specifically pontine omnipause
neurons and/or cerebellar Purkinje cells [4]. Twenty to forty
percent of OMS cases in adults and children are indicative
of an underlying malignancy [2, 5, 6]. The tumors most
frequently associated with OMS in children and adults are
neuroblastoma and small cell lung cancer (SCLC), respectively [7]. We describe an adult patient with OMS, who

was ultimately diagnosed with ductal adenocarcinoma of the
pancreas. To our knowledge, this is the third published report
of an association between OMS and pancreatic malignancy,
and the only case where the pancreatic malignancy was
detected prior to metastasis or autopsy at death [8, 9].

2. Case Presentation
Here we describe, a 72-year-old female with a history of
hypothyroidism, hyperlipidemia, hypertension, and 50 pack
years of smoking, who presented to an outside facility with a
30-pound weight loss, severe nausea, emesis, mild imbalance
which graduated to bedbound instability, and involuntary
body “shakes” progressing over 6 months. Initial investigations at an outside facility, including contrast enhancedMRI imaging of the entire neuroaxis, EEG, colonoscopy, and
basic hematologic and chemistry panels, were all normal. The
only initial abnormal findings were as follows: esophagogastroduodenoscopy (EGD) revealed possible gastritis, thyroid
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Figure 2: Endoscopic ultrasound (EUS) fine needle biopsy of
pancreas revealed adenocarcinoma with mucinous features.
Figure 1: Axial abdominal CT-scan showing dilatation of the
pancreas and duct cut-off sign (red arrow).

stimulating hormone was mildly elevated (9 U/mL), and antithyroid peroxidase antibody was elevated at 50 mg/L. She
was evaluated by a psychiatrist who prescribed sertraline,
as well as recommended relaxation techniques; however, her
family requested further evaluation, and she was transferred
to our institution. On physical exam, she had disorganized
high amplitude conjugate horizontal movements of her eyes
which persisted with eye closure, severe truncal ataxia that
prevented her from sitting up without support, and distinct
abdominal myoclonus. Otherwise, her neurological exam,
including detailed mental status exam testing, was unremarkable.
Symptomatic and empiric therapy with lorazepam, levetiracetam, and a 5-day course of high dose IV methylprednisolone was immediately initiated. Further work-up
revealed a lymphocytic pleocytosis in her cerebrospinal
fluid (CSF) of 25 WBCs, with an otherwise unremarkable
profile. Cytology was negative for malignancy and flow
cytometry demonstrated a T cell dominant inflammatory
process believed to be reactive. Paraneoplastic panel was
negative in the CSF; however, voltage-gated potassium channel antibodies (VGKC) were detected in her serum (0.05
nmol/L; normal <0.02 nmol/L). Notably, the CSF VGKC
assay was not yet available in our laboratory at the time of this
patient’s evaluation. Review of outside duodenal biopsy slides
obtained during EGD was consistent with acute H. Pylori
infection.
Computed tomography (CT) of the chest was normal. A
subtle pancreatic duct cut-off sign was noted on abdominal
CT, suggestive of a pancreatic mass (Figure 1). Subsequent
MRI and endoscopic ultrasound-guided fine needle biopsy
confirmed a ductal adenocarcinoma of the body of the
pancreas (Figure 2). The patient underwent laparoscopic
distal pancreatectomy and splenectomy, and a ductal adenocarcinoma, histologic grade 3/4 measuring 1.8 x 1.7 x 1.5 cm,
in the body of the pancreas was removed. Negative operative
margins were achieved, and all resected lymph nodes were

negative for metastasis. Acutely following surgical resection,
she experienced marked resolution of OMS symptoms. Upon
taper and discontinuation of levetiracetam, some of her
initial symptoms returned, including slight tremor and gait
instability; however, the opsoclonus did not recur. Repeat
serum paraneoplastic panel demonstrated VGKC normalization. She was initiated on single agent cisplatin-based
chemotherapy and appeared to be responding well; however,
she unfortunately died 7 months later, due to recurrent lung
infections and pulmonary compromise.

3. Discussion
While the cellular origin of OMS is unclear, the cause of
this dysfunction is likely autoimmune in nature. Although
classic cases of OMS describe anti-Ri antibody (otherwise
known as anti-neuronal nuclear autoantibody type 2 or
ANNA2) as the biological culprit, the presence of several other anti-neuronal and surface antibodies has been
confirmed, and these antibodies may be the mediators of
motor neuron dysfunction that causes OMS [2, 4, 10–12].
VGKC, for example, the surface antibody in our patient,
is a complex linked to the neuronal cell surface, and it
is typically associated with limbic encephalitis or Morvan’s
syndrome, defined by neuropsychiatric symptoms and muscle hyperexcitability [13, 14]. To our knowledge, this is the
first reported case of adult onset OMS associated with
VGKC.
In both children and adults, OMS is often an indicator of
an occult malignancy. In children, OMS is most commonly
associated with neuroblastoma; however, in adults, OMS
indicates the presence of cancer of the lung, breast, ovary,
thyroid, or Hodgkin’s Lymphoma [2, 15]. There is no current
diagnostic test for OMS because the antigen responsible for
initiating OMS has not been identified yet. Hence, the diagnosis of OMS is often clinical. The presence of involuntary,
saccadic eye movements, ataxia, gait incoordination, rigidity,
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and tremor, and the detection of surface or onconeural antibodies in serum or CSF are extremely useful in diagnosing
paraneoplastic OMS [15]. However, it is also common for
OMS symptoms to be observed prior to cancer diagnosis, as
was the case in our patient.
Treatment of OMS relies heavily on understanding the
pathogenesis of the disease process. In the case of occult
malignancy OMS, removal of the tumor, immunotherapy,
and symptomatic management can be beneficial, especially if
they are initiated in the early stages of symptom presentation,
rather than once deficits are well established [16, 17]. The
resolution of our patient’s opsoclonus, improvement of her
ataxia, and normalization of her neuronal antibodies following resection further support the hypothesis that her OMS
was of paraneoplastic origin.
This patient is unique in that she presented with typical symptoms of OMS, yet her symptoms were caused by
an underlying pancreatic adenocarcinoma, rather than a
more commonly associated malignancy (e.g., lung cancer,
breast cancer, and neuroblastoma). Importantly, her preclinical paraneoplastic symptoms provoked an aggressive
malignancy screen, revealing pancreatic dilatation with a
duct cut-off sign on CT. Upon resection, the patient’s tumor
was only 18 mm in greatest diameter. At this small size, the
pancreatic mass is a subtle finding on CT and MRI and is
only perceptible due to its obstruction of the main pancreatic
duct, due to an abrupt duct cut-off sign [18, 19]. Presence of
a duct cut-off sign should therefore prompt the clinician to
pursue a more invasive malignancy search, as in our case with
endoscopic biopsy.
Taken together, we highlight a rare case of OMS with
an unusual presentation manifested as a result of pancreatic
malignancy. Not only is this association with pancreatic
cancer atypical, this case emphasizes and reviews the importance of the duct cut-off sign as an indicator for underlying
pancreatic malignancy and highlights the next appropriate
step to ensure accurate structural evaluation when the duct
cut-off sign is observed in a patient with paraneoplastic
neurological symptoms.
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